Facilitating timely diagnosis and intervention for brain bleeds, the artificial intelligence (AI)-powered Viz ICH Plus software may provide quantified assessment for intracranial hyperdensities, lateral ventricles and midline shifts.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Viz ICH Plus software, which utilizes artificial intelligence (AI) to help quantify intracerebral hemorrhage on non-contrast computed tomography (CT) images.
For cases involving intracerebral hemorrhage, Viz ICH Plus offers automated detection, labeling, and volume quantification for segmentable brain structures, according to Viz.ai, the developer of the software.
The newly FDA-cleared Viz ICH Plus reportedly offers automated detection, labeling and volume quantification of intracerebral hemorrhage on non-contrast CT. (Image courtesy of Viz.ai.)
Given the critical nature of intracerebral hemorrhage, which reportedly accounts for 15 percent of strokes, the capability of Viz ICH Plus software to analyze intracranial hyperdensities, lateral ventricles and midline shifts may improve timely diagnosis and decision-making for appropriate treatments.
"The ability and mobility to obtain accurate and quantifiable measurements of intracerebral hemorrhages through Viz ICH Plus significantly enhances our decision-making process,” said Peter Kan, MD, MPH, FRCSC, FAANS, a professor and chair of the Department of Neurosurgery at the University of Texas Medical Branch. “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.